BioNeex Interviews

Chief Scientific and Medical officer of Endevica Bio, Daniel Marks, is sharing interesting insights about a new class of synthetic peptide mimetics designed to overcome the limitations of traditional peptides. The company’s lead candidate, Mifomelatide, targets the melanocortin system in the brain to counter the involuntary weight loss and muscle wasting seen in cancer cachexia, restoring appetite and body mass in clinical studies. Endevica is also developing 710GO, an oral MC3R/MC4R co-agonist that drives significant weight loss in preclinical models, offering a differentiated mechanism from current incretin-based obesity treatments.

Read Bioneex Story with Endevica Bio here